Company Analysis

BeyondSpring Inc. (BYSI)

Nasdaq: BYSI · Pharmaceutical Preparations · Florham Park, NJ · filing with the SEC since 2016
Grade4.8
◀ Past 3.8● Present 4.9▶ Future 5.3
5 est.
The companyfiscal 2025, as filed
Revenue$0.00
Net income-$1.0M+91.0%
Earnings per share$-0.02+92.9%
Operating cash flow-$19.8M-20.2%
Cash$7.8M+166.5%
Debtn/a
Shareholders’ equity-$24.0M-67.9%
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202634
Newest filingOct 29 · SCHEDULE 13G/A
Annual reportMar 25, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted21
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $0.00Net income -$6.7MCash from operations -$16.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 13, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 6, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 2, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 29, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 29, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 18, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BYSI · research, not advice